首页 > 市场调查报告书 > 製药

糖尿病

市场调查报告书

商品编码

1620344

全球糖尿病溃疡治疗市场规模：按治疗、按类型、按最终用户、按地区、范围和预测

Global Diabetic Ulcers Treatment Market Size By Treatment (Wound Care Dressings, Wound Care Devices), By Type (Foot Ulcer, Mouth Ulcer), By End-User (Hospitals And Clinics, Ambulatory Surgical Centers), By Geographic Scope And Forecast

出版日期: 2024年07月26日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

糖尿病溃疡治疗的市场规模与预测

2023年糖尿病溃疡治疗市场规模为91.7亿美元，预计2024年至2031年复合年增长率为5.40%，到2031年将达到134.4亿美元。糖尿病溃疡是一种主要发生在糖尿病患者的足部和小腿上的慢性伤口。这些溃疡是由于周围神经病变和血液交叉不良等问题而形成的，从而降低了身体癒合伤口的能力。糖尿病溃疡的治疗采用多学科策略，包括伤口护理、感染控制、血糖控制、伤口敷料、擦伤和生长因子等先进治疗。在严重的情况下，可能需要手术介入或高压氧治疗来加速康復并避免截肢等併发症。

随着全球糖尿病盛行率的不断上升，对高效糖尿病溃疡治疗的需求将急剧增加。生物技术和再生医学的进步正在推动该领域的创新，包括生物工程皮肤替代品、干细胞疗法和创新的伤口癒合剂。

远距医疗和人工智慧在伤口护理管理中的整合有可能透过实现远端监控和个人化治疗策略来改善患者的治疗结果。随着医疗保健系统转向预防措施和早期干预，糖尿病溃疡治疗市场预计将扩大，特别是在亚太地区和北美等糖尿病人口不断增长的地区。

糖尿病溃疡治疗的全球市场动态

塑造全球糖尿病溃疡治疗市场的关键市场动态

主要市场驱动因子

糖尿病盛行率增加：

根据国际糖尿病联盟的数据，预计 2021 年全球糖尿病患者人数将达到约 5.37 亿，2045 年将达到 7.83 亿。这种增长推动了对糖尿病溃疡治疗的需求，因为糖尿病会损害伤口癒合，导致更频繁的慢性溃疡以及感染和截肢等相关问题。随着糖尿病人口的增长，对降低风险并改善患者预后的有效伤口治疗的需求也在增加。

人口老化加剧：

世界卫生组织 (WHO) 预测，60 岁以上人口数量将从 2020 年的 10 亿增加到 2030 年的 14 亿。由于与年龄相关的循环和免疫功能的变化，糖尿病及其后果、伤口癒合不良和糖尿病溃疡在老年人中更为常见。随着人口老化的增加，对有效溃疡治疗解决方案的需求将会增加，以解决该年龄层慢性伤口风险增加和相关后果的问题。

医疗支出增加：

医疗保健支出的增加，尤其是在新兴国家，正在推动糖尿病溃疡治疗市场的发展。根据世界银行数据，全球卫生支出占GDP的比重从2000年的9.2%上升到2018年的9.8%。支出的增加将使人们能够更多地获得创新治疗、更强大的医疗保健基础设施以及更好的伤口护理管理。随着卫生预算的扩大，更多的资源被投入到慢性病管理，例如糖尿病溃疡治疗，并且患者获得专门和新颖治疗的机会正在改善。

主要问题

感染风险高：

糖尿病溃疡感染的风险很高，这会使治疗复杂化并延迟康復。日益严重的抗生素抗药性问题也加剧了这个问题，使得适当管理传染病变得困难。这延长了治疗的持续时间和成本，限制了现有药物的有效性和市场成长。

先进疗法的监管障碍：

干细胞、基因疗法和生物人造皮肤等先进药物需要严格的监管批准。漫长而昂贵的审批流程阻碍了新疗法向市场的推出。监管障碍阻止患者获得可能挽救生命的治疗方法并限制市场成长。

治疗费用高：

对许多患者来说，晚期糖尿病溃疡的治疗费用（包括生物工程皮肤替代品和干细胞治疗）可能太高，尤其是在欠发达国家。由于医疗保健系统和患者难以负担治疗费用，如此高的治疗成本限制了接受度并影响了整体市场成长。

癒合过程缓慢：

由于血液循环不良和血糖水平较高，糖尿病溃疡通常癒合缓慢。治癒率的延迟会增加治疗时间和成本，给医疗保健系统带来进一步的压力，限制有效治疗解决方案的可扩展性，并阻碍市场成长。

主要趋势：

伤口处理技术的进步：

生物工程皮肤替代品、生长激素和干细胞疗法等伤口治疗技术的进步将提高治疗糖尿病溃疡的效率。这些技术可加速癒合、降低感染风险并改善患者治疗效果，随着越来越多的医疗保健专业人员使用先进的伤口照护系统，市场将会扩大。

远距医疗的普及：

远距医疗在糖尿病溃疡治疗中越来越受欢迎，因为它允许远端监控患者和评估伤口。这种趋势对于居住在偏远地区或无法经常去医院就诊的患者尤其有利。远距医疗因其便利性和可近性而被采用，提高了患者的依从性并允许早期干预。

将人工智慧 (AI) 融入伤口护理：

人工智慧 (AI) 越来越多地应用于糖尿病溃疡管理，以帮助医疗保健临床医生预测伤口癒合结果、追踪治疗进度并推荐量身定制的治疗策略，我正在这样做。人工智慧提高了诊断准确性和治疗效果，透过增强整体患者护理和简化治疗方法来推动市场成长。

Diabetic Ulcers Treatment Market size was valued at USD 9.17 Billion in 2023 and is projected to reach USD 13.44 Billion by 2031, growing at a CAGR of 5.40% from 2024 to 2031. Diabetic ulcers are chronic wounds that primarily affect the feet and lower extremities of diabetics. These ulcers form as a result of issues such as peripheral neuropathy and poor circulation, which reduce the body's capacity to heal wounds properly. Diabetic ulcers are treated using a multidisciplinary strategy that includes wound care, infection control, glucose management, and advanced therapies such as wound dressings, debridement, and growth factors. In severe situations, surgical intervention or hyperbaric oxygen therapy may be necessary to promote recovery and avoid complications such as amputation.

The increased prevalence of diabetes globally, the demand for efficient diabetic ulcer therapies is likely to increase dramatically. Biotechnology and regenerative medicine advancements are driving innovation in the field, including bioengineered skin substitutes, stem cell therapies, and innovative wound healing agents.

The integration of telemedicine and artificial intelligence in wound care management has the potential to improve patient outcomes by allowing for remote monitoring and individualized treatment strategies. As healthcare systems shift toward preventative measures and early interventions, the market for diabetic ulcer therapy is expected to grow, particularly in regions with growing diabetes populations, such as Asia-Pacific and North America.

Global Diabetic Ulcers Treatment Market Dynamics

The key market dynamics that are shaping the global diabetic ulcers treatment market include:

Key Market Drivers:

Increasing Prevalence of Diabetes:

The rising incidence of diabetes is a primary driver of the diabetic ulcer treatment market, with roughly 537 million adults affected globally in 2021 and a predicted 783 million by 2045, according to the International Diabetes Federation. This increase has driven up demand for diabetic ulcer treatments since diabetes hinders wound healing, resulting in a higher frequency of chronic ulcers and associated problems such as infections and amputations. As the diabetes population expands, so will the demand for effective wound care treatments to mitigate risks and enhance patient outcomes.

Growing Aging Population:

The growing aging population is a major driver of the diabetic ulcer treatment market, with the World Health Organization predicting that the number of individuals aged 60 and over will increase from 1 billion in 2020 to 1.4 billion by 2030. Diabetes and its consequences, such as poor wound healing and diabetic ulcers, are more common in older persons due to changes in circulation and immunological function caused by aging. As the older population grows, the demand for efficient ulcer treatment solutions will rise to meet the increased risk of chronic wounds and accompanying consequences in this age range.

Increasing Healthcare Expenditure:

Increasing healthcare expenditure, particularly in emerging nations, is propelling the diabetic ulcer treatment market. According to World Bank data, global health expenditure as a proportion of GDP increased from 9.2% in 2000 to 9.8% in 2018. This increased spending enables greater access to innovative treatments, enhanced healthcare infrastructure, and better wound care management. As healthcare budgets expand, more resources are directed into chronic disease management, such as diabetic ulcer treatments, improving patient access to specialized care and novel therapies.

Key Challenges:

High Risk of Infection:

Diabetes ulcers have a high risk of infection, which can complicate therapy and slow recovery. The growing issue of antibiotic resistance exacerbates this problem, making it difficult to properly manage infections. This lengthens treatment times and expenses, restricting the efficacy of current medicines and market growth.

Regulatory Barriers for Advanced Therapies:

Advanced medicines such as stem cells, gene therapy, and bioengineered skin substitutes are subject to demanding regulatory approval. Long and expensive approval processes impede the introduction of novel treatments to the market. Regulatory hurdles impede patient access to potentially life-saving treatments, limiting market growth.

High Treatment Costs:

Treatment costs for advanced diabetic ulcers, including bioengineered skin substitutes and stem cell therapies, might be too expensive for many patients, particularly in underdeveloped nations. The high cost of these treatments limits acceptance and has an impact on overall market growth, as healthcare systems and patients struggle to afford them.

Slow Healing Process:

Diabetic ulcers typically heal slowly due to poor circulation and high blood sugar levels. The delayed rate of healing increases the length and cost of care, putting additional strain on healthcare systems and restricting the scalability of effective treatment solutions, stifling market growth.

Key Trends:

Advances in Wound Care Technologies:

Advances in wound care technology, including bioengineered skin substitutes, growth hormones, and stem cell therapies, enhance the efficiency of diabetic ulcer treatments. These technologies promote faster healing, lower infection risks, and improve patient outcomes, resulting in market development as more healthcare providers use advanced wound treatment systems.

Increasing Adoption of Telemedicine:

Telemedicine is gaining traction in diabetic ulcer treatment as it allows for remote patient monitoring and wound assessment. This trend is especially advantageous for patients who live in remote areas or are unable to travel frequently to the clinic. Telemedicine is being adopted due to its convenience and accessibility, which improves patient compliance and allows for early intervention.

Integration of Artificial Intelligence (AI) in Wound Care:

Artificial Intelligence (AI) is increasingly being used in diabetic ulcer management, assisting healthcare clinicians in predicting wound healing outcomes, tracking treatment progress, and recommending tailored care strategies. AI improves diagnostic accuracy and treatment efficacy, resulting in market growth by enhancing overall patient care and streamlining treatment methods.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Diabetic Ulcers Treatment Market Regional Analysis

Here is a more detailed regional analysis of the global diabetic ulcers treatment market:

North America:

North America currently dominates the global diabetic ulcer treatment market, which is projected to continue in the coming years. One of the primary factors is the high incidence of diabetes in the region, with the Centers for Disease Control and Prevention (CDC) claiming that 37.3 million Americans, or 11.3% of the population, had diabetes in 2021. This figure is expected to increase rapidly, reaching 60.6 million by 2060.

The region has a higher-than-average incidence of diabetic foot ulcers, with a 2022 study in the Journal of the American Medical Association (JAMA) indicating an annual rate of 2.2%, which is projected to rise to 2.5% by 2030. These causes, combined with an aging population, increase the patient pool as older persons are more susceptible to diabetes and accompanying problems.

North America's strong healthcare infrastructure and significant research investments are also driving market expansion. In 2020, the National Institutes of Health (NIH) will invest USD 1.15 Billion in diabetes research, promoting innovation in therapies for diabetic complications such as ulcers. Rising healthcare spending in the United States, expected to reach USD 6.2 Trillion by 2028, supports further investment in advanced ulcer therapies. These characteristics, together with a growing older population and continuing advances in medical technology, are driving North America's leadership in the diabetic ulcer treatment market.

Asia Pacific:

The Asia Pacific region's fastest-growing to the top of the list for diabetic ulcer treatment markets. One of the key factors is the region's increasing prevalence of diabetes, notably in China and India. According to the International Diabetes Federation's (IDF) Diabetes Atlas 2021, the Western Pacific area had 206 million adults with diabetes in 2021, with the amount expected to climb to 260 million by 2045. This increase dramatically raises the number of individuals at risk of acquiring diabetic complications including foot ulcers, which currently afflict millions.

Furthermore, increased healthcare expenditure and improved healthcare infrastructure are important drivers driving market expansion. According to the World Health Organization (WHO), health spending in the Asia Pacific region has grown at an average annual rate of 6.7%, outperforming economic development, while countries such as China seek to expand healthcare spending to 7% of GDP by 2030. The region's vast and aging population also plays an important role, with the number of persons aged 60 and up predicted to more than double by 2050. This demographic shift, together with increased knowledge of diabetic complications and improved healthcare access, positions the Asia-Pacific area as an essential market for diabetic ulcer therapy in the coming years.

Global Diabetic Ulcers Treatment Market: Segmentation Analysis

The Global Diabetic Ulcers Treatment Market is Segmented on the basis of Treatment, Type, End-User, And Geography.

Diabetic Ulcers Treatment Market, By Treatment

Wound Care Dressings
Wound Care Devices
Active Therapies

Based on Treatment, the market is bifurcated into Wound Care Dressings, Wound Care Devices, and Active Therapies. Wound care dressings dominate as they are widely used to treat a variety of ulcers, including diabetic foot ulcers. Hydrocolloid, foam, and antimicrobial dressings serve to keep the healing environment wet, lower the risk of infection, and promote faster recovery. Active therapies are the fastest-growing area, due to advances in bioengineered skin substitutes, growth factors, and stem cell therapies, which provide more effective options for difficult-to-heal diabetic ulcers, especially in cases when conventional treatments are ineffective.

Diabetic Ulcers Treatment Market, By Type

Foot Ulcer
Mouth Ulcer
Skin Ulcer

Based on Type, the market is segmented into Foot Ulcer, Mouth Ulcer, and Skin Ulcer. The foot ulcer segment is currently dominant due to the high frequency of diabetic foot ulcers among diabetics, which is exacerbated by variables such as neuropathy and poor circulation, all of which increase the risk of foot injuries and infections. The mouth ulcer segment is expanding at a rapid pace, owing to increased knowledge and better diagnostic procedures for diabetic oral complications, as well as an increase in lifestyle-related variables contributing to oral health problems. This development reflects a larger recognition of the need to address all types of ulcers in diabetes individuals in order to enhance overall health.

Diabetic Ulcers Treatment Market, By End-User

Hospitals And Clinics
Ambulatory Surgical Centers
Academic and Research Organizations

Based on End-User, the market is segmented into Hospitals and Clinics, Ambulatory Surgical Centers, and Academic and Research Organizations. Hospitals and clinics dominate the market, owing to their extensive healthcare offerings, superior wound care facilities, and access to specialized medical professionals capable of effectively managing severe diabetic ulcer patients. This component is essential for providing inpatient and outpatient care, guaranteeing a comprehensive approach to treatment. Ambulatory surgery facilities are the fastest-growing group, driven by an increasing desire for outpatient operations, cost-effectiveness, and a growing demand for minimally invasive therapies. These centers are becoming increasingly popular for wound management and ulcer surgery, indicating a shift toward more accessible and efficient patient care.

Key Players

The "Global Diabetic Ulcers Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
ConvaTec Group Plc, Smith & Nephew Plc, 3M Company, Coloplast AS, B. Braun SE, Medline Industries LP, MiMedx Group, Inc., Organogenesis Inc., URGO Medical, Healthium Medtech, Molnlycke Healthcare, Paul Hartmann AG, and Systagenix Wound Management.
The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Diabetic Ulcers Treatment Market Recent Developments
In April 2023, 3M Health Care's revolutionary 3M Veraflo therapy, which includes both 3M Veraflo cleanse choice complete dressing and 3M V.A.C. Veraflo cleanse choice dressing, obtained FDA approval for the hydromechanical removal of infectious materials, non-viable tissue, and wound debris. This enabled the company to expand its treatment type offers and launch new treatment types into the market.
In June 2022, Smith & Nephew will launch a new R&D and manufacturing facility in Hull, UK, for its advanced wound treatment franchise. This strategy enabled the corporation to expand its research operations and enhance its production capacity

1 INTRODUCTION OF GLOBAL DIABETIC ULCERS TREATMENT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL DIABETIC ULCERS TREATMENT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY TREATMENT

5.1 Overview
5.2 Wound Care Dressings
5.3 Wound Care Devices
5.4 Active Therapies

6 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY TYPE

6.1 Overview
6.2 Foot Ulcer
6.3 Mouth Ulcer
6.4 Skin Ulcer

7 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY END-USER

7.1 Overview
7.2 Hospitals and Clinics
7.3 Ambulatory Surgical Centers
7.4 Academic and Research Organizations

8 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL DIABETIC ULCERS TREATMENT MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 ConvaTec Group Plc
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Smith & Nephew Plc
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 3M Company
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Molnlycke Health Care AB
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Coloplast AS
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 B. Braun SE
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Medline Industries LP
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 MiMedx Group Inc.
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Organogenesis Inc.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 URGO Medical
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments